Clinical trials: Tumours, Gynecological, open to volunteers
- Condition Tumours, Gynecological
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Gynecological Malignancies
A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic Malignancies
This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with recurrent or metastatic gynecologic malignancies.
- Trial name
- NCT06131450
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Tumours, Gynecological
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns.
- Trial name
- NCT06796907
- Testing
- Mo-Rez, Dostarlimab, Bevacizumab
- Where
- 82 sites in United States, Argentina and 21 more
- Volunteers
- 305 people
- Sponsor
- GlaxoSmithKline
Gynecological Tumors, Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors
This Phase Ib/II study is a clinical study to explore the efficacy and safety of BL-M08D1 for injection in patients with recurrent or metastatic gynecological tumors and other solid tumors.
- Trial name
- NCT07793825
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gynecological Malignancies, Solid Tumors
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors
This study is a single-arm, open-label, multicenter, non-randomized phase II clinical study evaluating the efficacy and safety of BL-M09D1 for injection in patients with locally advanced or metastatic gynecological malignancies…
- Trial name
- NCT07769229
- Testing
- BL-M09D1
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gynecological Tumors, Solid Tumors
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of SI-B036 bispecific…
- Trial name
- NCT07778862
- Testing
- SI-B036
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Gynecological Malignancies
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
This is an open-label, multicenter, Phase II clinical study to evaluate the efficacy and safety of SKB518 as monotherapy or combination therapy in patients with advanced gynecological malignancies.
- Trial name
- NCT07448922
- Testing
- SKB518 for injection, Carboplatin (AUC 5), Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 280 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Advanced Gynecological Malignancies
Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies
This study is a single-arm, open-label, multicenter Phase IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of BRY812 for Injection in patients with LIV-1-positive advanced gynecological…
- Trial name
- NCT07311538
- Testing
- BRY812 for injection
- Volunteers
- 56 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Gynecological Malignant Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
- Trial name
- NCT05803018
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gynecological Tumors
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of…
- Trial name
- NCT06798207
- Testing
- TQB2102 for injection
- Where
- 31 sites in China
- Volunteers
- 170 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gynecological Malignancies
9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.
- Trial name
- NCT06926998
- Testing
- 9MW2821+other anticancer therapy
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Advanced Gynecological Malignancy
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.
- Trial name
- NCT06654440
- Testing
- SHR-A2102 for injection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.